These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 34389633)

  • 1. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis.
    Weisel K; Scott N; Berger S; Wang S; Brown K; Powell M; Broer M; Watts C; Tompson DJ; Burriss SW; Hawkins S; Abbott-Banner K; Tak PP
    BMJ Open Gastroenterol; 2021 Aug; 8(1):. PubMed ID: 34389633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
    Weisel K; Berger S; Thorn K; Taylor PC; Peterfy C; Siddall H; Tompson D; Wang S; Quattrocchi E; Burriss SW; Walter J; Tak PP
    Arthritis Res Ther; 2021 Mar; 23(1):85. PubMed ID: 33726834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.
    Weisel K; Scott NE; Tompson DJ; Votta BJ; Madhavan S; Povey K; Wolstenholme A; Simeoni M; Rudo T; Richards-Peterson L; Sahota T; Wang JG; Lich J; Finger J; Verticelli A; Reilly M; Gough PJ; Harris PA; Bertin J; Wang ML
    Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects.
    Tompson DJ; Davies C; Scott NE; Cannons EP; Kostapanos M; Gross AS; Powell M; Ino H; Shimamura R; Ogura H; Nagakubo T; Igarashi H; Nakano A
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):71-83. PubMed ID: 33165774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Ludbrook VJ; Budd DC; Thorn K; Tompson D; Votta BJ; Walker L; Lee A; Chen X; Peppercorn A; Loo WJ
    Dermatol Ther (Heidelb); 2024 Feb; 14(2):489-504. PubMed ID: 38372938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to Inhibition of Receptor-Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo-Controlled Study.
    Weisel K; Berger S; Papp K; Maari C; Krueger JG; Scott N; Tompson D; Wang S; Simeoni M; Bertin J; Peter Tak P
    Clin Pharmacol Ther; 2020 Oct; 108(4):808-816. PubMed ID: 32301501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772.
    Tompson DJ; Whitaker M; Pan R; Johnson G; Fuller T; McKenzie L; Zann V; Powell M; Abbott-Banner K; Hawkins S
    Pharm Res; 2021 Jul; 38(7):1235-1245. PubMed ID: 34136987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Haifer C; Paramsothy S; Kaakoush NO; Saikal A; Ghaly S; Yang T; Luu LDW; Borody TJ; Leong RW
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):141-151. PubMed ID: 34863330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology.
    Tompson D; Whitaker M; Pan R; Johnson G; Fuller T; Zann V; McKenzie L; Abbott-Banner K; Hawkins S; Powell M
    Pharm Res; 2022 Jan; 39(1):153-165. PubMed ID: 34988780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RIPK1 inhibitor ameliorates colitis by directly maintaining intestinal barrier homeostasis and regulating following IECs-immuno crosstalk.
    Lu H; Li H; Fan C; Qi Q; Yan Y; Wu Y; Feng C; Wu B; Gao Y; Zuo J; Tang W
    Biochem Pharmacol; 2020 Feb; 172():113751. PubMed ID: 31837309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate for induction of remission in ulcerative colitis.
    Chande N; Wang Y; MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD006618. PubMed ID: 25162749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme.
    Sandborn WJ; Nguyen DD; Beattie DT; Brassil P; Krey W; Woo J; Situ E; Sana R; Sandvik E; Pulido-Rios MT; Bhandari R; Leighton JA; Ganeshappa R; Boyle DL; Abhyankar B; Kleinschek MA; Graham RA; Panes J
    J Crohns Colitis; 2020 Sep; 14(9):1202-1213. PubMed ID: 32161949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.